Opinion|Podcasts|November 8, 2024
Role of Testing in CSU Diagnosis
Key Takeaways
- Routine blood tests, such as ESR, CRP, IgG anti-TPO, and total IgE, are recommended for diagnosis.
- Biopsy is generally not required for diagnostic testing in this context.
Panelists discuss the recommended diagnostic testing for chronic spontaneous urticaria (CSU), noting that extensive testing is not necessary and that routine blood counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IgG anti-thyroid peroxidase (TPO), and total IgE are adequate, while also addressing the limited role of biopsy; they further explore how disease severity is assessed using tools like Urticaria Activity Score (UAS7) and Urticaria Control Test (UCT).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Is testing recommended for diagnosis, and if so, which kind?
- Extensive testing not needed: routine blood count. ESR and/or CRP, and IgG anti-TPO and total IgE (according to guidelines)
- What is the role, if any, of biopsy in diagnostic testing?
- How is disease severity assessed?
- UAS7
- UCT
Advertisement
Related to this article
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD
5